Blog

Home  >  Resources  >  Blog

INSIDE THIS ISSUE CMS News 2019-2020 Influenza Vaccine Season NDCs Now Available New HCPCS Code J0642-Injection, levoleucovorin (khapzory), 0.5 mg and Revised Code Description for J0641-levoleucovorin, 0.5mg Coming Soon New HCPCS Drug Q-Codes effective October 1, 2019 New HCPCS Drug J-Codes effective October 1, 2019 New HCPCS Drug Code Revisions and Discontinuations effective October 1, […]

In September there was 1 new drug approval by the FDA we deemed specific to the specialty market. In addition, there were 9 supplemental drug approvals. The FDA had acted on assignment of 4 new product reviews. Drugs included in this review are generally regarded by the industry as specialty drugs.  Qualifiers may include anticipated […]

Join RJ’s Jason Young – SVP Clinical Data Operations, Todd Cooperman – SVP Clinical Insights and Analytics, and Chris Webb – Director of Product Development, as they review the drug coding updates, revisions, and issues observed over 2019’s third quarter. October 8th, 2pm EST Learn about: New and Existing Code Updates – HCPCS Codes: J […]

Wondering about the different types of HCPCS (Healthcare Common Procedure Coding System) codes and how they apply to reimbursement? Chris and Jason walk through HCPCS and CPT® (Current Procedural Terminology) code background in this edition of Drug Pricing and Reimbursement 101. These webinar clips from “Shedding Light on Medically Covered Specialty Drug Pricing Methods” touch […]

INSIDE THIS ISSUE CMS News 2019-2020 Influenza Vaccine Season NDCs Now Available New HCPCS Drug Q-Codes effective October 1, 2019 New HCPCS Drug J-Codes effective October 1, 2019 New HCPCS Drug Code Revisions and Discontinuations effective October 1, 2019 Drug Reimbursement Code Price Updates 48 Drug Codes required a recalculation of their AWP Code Price Drugs/Devices […]

In August there were 4 new drug approvals by the FDA we deemed specific to the specialty market. In addition, there were 2 supplemental drug approvals. The FDA had acted on assignment of 5 new product reviews. Drugs included in this review are generally regarded by the industry as specialty drugs.  Qualifiers may include anticipated […]

The winners of the 2019 RJ Health Innovation Challenge, a competition designed to inspire innovation and engagement among our team, were announced at an awards luncheon held at the company’s headquarters in Middletown, CT. Jason Young, Kelly Black, Paul Rector, and Cristina Arnold RJ Health has historically engaged its employees through similar challenges, along with […]

Join RJ’s Product and Clinical teams as they walk through the multitude of different combinations of drug claims and pricing methodologies, via clips from the webinar “Shedding Light on Medically Covered Specialty Drug Pricing Methods.” In the following clip, Chris Webb explains the application and breakdown of the NDC or National Drug Code. All past […]

INSIDE THIS ISSUE CMS News 2019-2020 Influenza Vaccine Season NDCs Now Available Drug Reimbursement Code Price Updates Drugs/Devices New Clinical and Billing Information CODE UPDATES Large Price Changes: We identify and report on the codes with the most substantial pricing increases or decreases each month and detail the rationale for the change. Of the 87 […]

In July there were six new drug approvals by the FDA we deemed specific to the specialty market, three of the approvals were for biosimilar products. In addition, there were 2 supplemental drug approvals. The FDA had acted on assignment of eight new product reviews. Drugs included in this review are generally regarded by the […]